Dr. Bradley Monk discusses the novel PARP inhibitors (PARPi) in clinical development for advanced ovarian cancers and provides the clinical context for their integration into existing treatment paradigms. The biology of ovarian cancers, latest trial data with PARPi, the potential for patient selection, and the ongoing phase III clinical studies are highlighted.

Earn accreditation for this activity at the following location:
[ Ссылка ]

© 2014 Imedex, LLC.

свернуть